Breaking News

Frontage Supports Eisai & Biogen Bioanalysis of Lecanemab

Lecanemab is an experimental drug being jointly developed by Biogen and Eisai in clinical trials for the treatment of Alzheimer's disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Frontage’s Bioanalytical team has partnered with Eisai and Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in the U.S. and China. Eisai and Biogen recently acheived favorable results of the lecanemab (BAN2401) Clarity AD study. Lecanemab is an experimental drug being jointly developed by Biogen and Eisai that’s currently in clinical trials for the treatment of Alzheimer’s disease.   The Frontage tea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters